TransMedics Group, Inc. (TMDX) Stock

About TransMedics Group, Inc.

TransMedics Group, Inc. (TMDX) stock trades at $70.74 with a market capitalization of $2.45B. The stock is valued at a price-to-earnings (P/E) ratio of 18.50, price-to-book of 5.46, price-to-sales of 4.23. Over the past 52 weeks the stock has ranged between $60.10 and $156.00, and currently trades 54.7% below its 52-week high.

On profitability, TransMedics Group, Inc. generates a return on equity (ROE) of 32.97%, above the typical market range of roughly 12-15%, return on capital employed of 5.97%, an operating margin of 14.85%, a net profit margin of 22.69%.

TransMedics Group, Inc. by the numbers, 2016–2025

Between 2016 and 2025 TransMedics Group, Inc. reported revenue of $6.0M rising to $605.0M, a change of +9983.3% across 10 years. Compounded, revenue has grown 87.7% a year over five years, 86.7% over three, 36.9% over the last twelve months. Net profit rose to $190.0M.

Operating margin went from -370.2% in 2016 to 17.9% in 2025, a gain of 388.1 percentage points. The most recent net margin is 22.69%. On a trailing twelve-month basis to Jun '26, revenue is $669.0M and net profit $151.0M.

Borrowings rose from $8.0M to $470.0M, cash from operations was $193.0M in the latest year, positive in 2 of the last 10.

Return on equity has averaged -9.3% over five years, and was 40.2% in the most recent year.

The share price itself has compounded at 24.2% a year over five years, -5.5% over three, -46.2% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

TransMedics Group, Inc. (TMDX) — frequently asked questions